Skip to main content

Pharvaris N.V.

corporate_fare Company Profile

Pharvaris N.V.

PHVS·NASDAQ·Life Sciences·CIK 0001830487

Pharvaris N.V. is a late-stage biopharmaceutical company that develops and commercializes therapies for rare diseases with unmet needs, specifically focusing on angioedema and other diseases mediated by bradykinin. The company's primary product is deucrictibant, a small molecule bradykinin B2-receptor antagonist. Deucrictibant is being developed to treat attacks caused by bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH). This therapy is currently in Phase 3 trials for the treatment of HAE attacks and also in Phase 3 trials for the prophylaxis (prevention) of HAE attacks. Pharvaris N.V. is developing both an extended-release tablet and an immediate-release capsule formulation of deucrictibant. The company was incorporated in 2015 and its headquarters are located in Zug, Switzerland.

Pharvaris N.V. (NASDAQ:PHVS) is a publicly traded company in the Life Sciences sector. Wiseek monitors PHVS SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Pharvaris Confirms H1 2026 NDA Submission for HAE Treatment, Details 2025 Financials and Recent $124M Capital Raise
  • Pharvaris Extends Cash Runway Into 2028 After Offering Closes
  • Pharvaris Secures $124M Net from Offering, Extends Cash Runway to 2028, Reports Improved Q1 Loss
  • Pharvaris Closes $132.3M Public Offering, Including Full Over-Allotment Exercise
  • Pharvaris Closes $132.3M Offering, Underwriters Fully Exercise Option

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$175.7M
Diluted EPS
-$2.97
Op. Cash Flow
-$137.07M
Free Cash Flow
-$137.24M
Operating Income
-$173.71M
Cash & Equivalents
$291.68M
Debt / Equity
0.00×
Shares Outstanding
65.21M sh
Source: 20-F · filed 2026-04-02 · accession 0001830487-26-000013

Insider Transactions

PHVS files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with P →
$30.72
52-week range · as of 2026-06-11 $16 – $33.33
Market cap
$2.15B
Volume
180.2K (0.5× avg)
3-mo avg 392.2K
Live data · 2026-06-14 03:50 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed PHVS - Latest Insights

PHVS
Jun 11, 2026, 6:52 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $32.13
Real-time Price: $30.72 info
Change: -$1.41 (-4%) info
Market Cap: $2.146B info
PHVS
May 12, 2026, 4:21 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $31.25
Real-time Price: $30.72 info
Change: -$0.530 (-2%) info
Market Cap: $2.146B info
PHVS
May 12, 2026, 4:05 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $32.00
Real-time Price: $30.72 info
Change: -$1.28 (-4%) info
Market Cap: $2.146B info
PHVS
May 11, 2026, 4:41 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $30.00
Real-time Price: $30.72 info
Change: +$0.720 (+2%) info
Market Cap: $2.146B info
PHVS
May 11, 2026, 4:15 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $30.00
Real-time Price: $30.72 info
Change: +$0.720 (+2%) info
Market Cap: $2.146B info
PHVS
May 08, 2026, 5:13 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $30.09
Real-time Price: $30.72 info
Change: +$0.630 (+2%) info
Market Cap: $2.146B info
PHVS
May 08, 2026, 6:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $29.20
Real-time Price: $30.72 info
Change: +$1.52 (+5%) info
Market Cap: $2.146B info
PHVS
Apr 02, 2026, 6:52 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $27.60
Real-time Price: $30.72 info
Change: +$3.12 (+11%) info
Market Cap: $2.146B info
PHVS
Apr 02, 2026, 6:51 AM EDT
Filing Type: 20-F
Importance Score:
8
Price at Filing: $27.37
Real-time Price: $30.72 info
Change: +$3.35 (+12%) info
Market Cap: $2.146B info
PHVS
Apr 02, 2026, 6:50 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $27.37
Real-time Price: $30.72 info
Change: +$3.35 (+12%) info
Market Cap: $2.146B info
PHVS
Mar 02, 2026, 6:50 AM EST
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $28.39
Real-time Price: $30.72 info
Change: +$2.33 (+8%) info
Market Cap: $2.146B info
PHVS
Jan 12, 2026, 6:51 AM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $25.89
Real-time Price: $30.72 info
Change: +$4.83 (+19%) info
Market Cap: $2.146B info